Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
Piper Sandler Reiterates Overweight Rating on Moderna (MRNA) Following FDA Approval of mRNA Flu Vaccine
August 6, 2026 8:42 AM EDTPiper Sandler analyst Edward Tenthoff reiterated an Overweight rating and a $77.00 price target on Moderna (NASDAQ: MRNA) following the FDA's approval of the company's mRNA flu vaccine.
The analyst commented, "The FDA granted approval for mFLUSIVA (mRNA-1010) to prevent seasonal influenza infection... More
